Fosun app lets China users get BioNTech COVID vaccines in Hong Kong
China‘s Shanghai Fosun Pharmaceutical Group said users of its mobile health app in China can now register to take COVID-19 booster shots in Hong Kong using BioNTech’s vaccine.
The booster shots offered are recommended for those aged 18 and above and those who have completed their initial course of vaccination, according to the Shanghai-listed company.
The announcement came as mainland China took a major step towards easing COVID-19 border controls, with Chinese policymakers deeming the Omicron variant of the new coronavirus to have weakened in pathogenicity.
China has so far insisted on using only Chinese-made vaccines for its own population, which are of the inactivated virus type and not based on Western mRNA technology.
BioNTech and its partner in China, Fosun, were granted approval for their COVID-19 vaccine, which is adapted for the BA.4 and BA.5 subvariants of Omicron, for people aged 12 and older in Hong Kong, the German company said on Dec. 23.
The vaccine is the first and currently only variant-adapted vaccine available as a booster dose for individuals 12 years of age and older that has been granted approval in Hong Kong, BioNTech said at the time.
Fosun did not immediately respond to a request for comment.
A shipment of BioNTech COVID-19 vaccines meant for German nationals in China arrived at the German embassy in Beijing last week as cases in China soared after policymakers dropped nearly all of their previous epidemic control protocols.
FacebookTwitterLinkedin
China‘s Shanghai Fosun Pharmaceutical Group said users of its mobile health app in China can now register to take COVID-19 booster shots in Hong Kong using BioNTech’s vaccine.
The booster shots offered are recommended for those aged 18 and above and those who have completed their initial course of vaccination, according to the Shanghai-listed company.
The announcement came as mainland China took a major step towards easing COVID-19 border controls, with Chinese policymakers deeming the Omicron variant of the new coronavirus to have weakened in pathogenicity.
China has so far insisted on using only Chinese-made vaccines for its own population, which are of the inactivated virus type and not based on Western mRNA technology.
BioNTech and its partner in China, Fosun, were granted approval for their COVID-19 vaccine, which is adapted for the BA.4 and BA.5 subvariants of Omicron, for people aged 12 and older in Hong Kong, the German company said on Dec. 23.
The vaccine is the first and currently only variant-adapted vaccine available as a booster dose for individuals 12 years of age and older that has been granted approval in Hong Kong, BioNTech said at the time.
Fosun did not immediately respond to a request for comment.
A shipment of BioNTech COVID-19 vaccines meant for German nationals in China arrived at the German embassy in Beijing last week as cases in China soared after policymakers dropped nearly all of their previous epidemic control protocols.
FacebookTwitterLinkedin
Denial of responsibility! Techno Blender is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials, please contact us by email – [email protected]. The content will be deleted within 24 hours.